Ari Samuel Hilibrand

Mr. Ari Samuel Hilibrand


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in JBJS Open Access
Verified
Journal Article
Open access
AHAri Samuel Hilibrand
Ari Samuel Hilibrand
LRLee E Rubin
Lee E Rubin
JGJonathan N Grauer
Jonathan N Grauer
Background: Over 1 million joint arthroplasties are performed annually in the United States. Ideally, as devices and surgical techniques improve, the number of revision arthroplasties relative to primary arthroplasties should decrease. To our knowledge, this is the first study to evaluate state-by-state disparities in the ratio of revision to primary knee arthroplasty (unicompartmental and total) and total hip arthroplasty (THA). Methods: The National Inpatient Sample was used to identify patients who had undergone primary or revision knee arthroplasty or primary or revision THA from 2001 to 2011. Demographic characteristics, surgical rates, and revision ratios (the number of revision procedures divided by the number of primary procedures) were determined for the United States as a whole and by state. Results: During the study window, 47 states were sampled. For knee arthroplasty, 1,251,484 patients were identified: 91% underwent primary procedures and 9% underwent revision procedures. Compared with the primary knee arthroplasty cohort, the revision knee arthroplasty cohort had a younger mean age, had more male patients, and had more chronic conditions and longer hospitalizations (p < 0.001 for each). Over the years studied, the mean age of patients who had undergone primary knee arthroplasty decreased 1.8 years (p < 0.0001) and the mean age of those who had undergone revision knee arthroplasties decreased 2.4 years (p < 0.0001). The national revision ratio remained unchanged at around 0.1 (p = 0.8792). However, there was a 2.2-fold variation in revision ratio by state (revision ratio state range, 0.065 to 0.141). For THA, 614,638 patients were identified: 85% underwent primary procedures and 15% underwent revision procedures. Compared with the primary THA cohort, the revision THA cohort had an older mean age, had fewer male patients, and had more chronic conditions and longer hospitalizations (p < 0.001 for each). Over the years studied, the mean age of patients who had undergone primary THA decreased 1.5 years (p = 0.0016), whereas patients who had undergone revision had no significant age trend (p = 1.0000). Unlike for knee arthroplasty, the national THA revision ratio trended downward (0.24 evolved to 0.18, p = 0.0016), and there was a 2.1-fold variation in the revision ratio by state (revision ratio state range, 0.119 to 0.248). Conclusions: This study found significant variability in state-by-state revision ratios. It also found that the national revision ratio stayed relatively steady for knee arthroplasty but was decreasing for THA, and that patients who had undergone revision knee arthroplasty were getting younger, whereas patients who had undergone revision THA were not. These discrepancies suggest divergent histories for primary knee arthroplasty and THA and warrant further detailed evaluation. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.

1 April 2021 in JAAOS: Global Research and Reviews
Verified
Journal Article
Open access
MMMichael R. Mercier
Michael R. Mercier
NPNeil Pathak
Neil Pathak
MAMurillo Adrados
Murillo Adrados
AGAnoop R. Galivanche
Anoop R. Galivanche
RMRohil Malpani
Rohil Malpani
JGJonathan N Grauer
Jonathan N Grauer
Introduction: The Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey is a federally mandated survey that assesses patient satisfaction after hospitalization. It has been noted that a minority of patients actually return the survey. Potential bias in who does and does not respond to the survey (nonresponse bias) after total hip arthroplasty (THA) may affect the survey results. Methods: All adult patients undergoing inpatient elective primary THA between February 2013 and May 2020 at a single institution were selected for retrospective analysis. After discharge, all had been mailed the HCAHPS survey, and the primary outcome for the current study was survey return. Patient characteristics and 30-day perioperative outcomes were assessed. Univariate and multivariate analyses were performed to determine correlations between the above variables and HCAHPS survey return status. Results: Of 3,310 THA patients analyzed, 1,049 (31.69%) returned the HCAHPS surveys. On multivariate regression analyses, patients who did not return the survey were more likely to have a higher American Society of Anesthesia score (score of three or higher, odds ratio [OR] = 2.27; P < 0.001), be more functionally dependent (OR = 2.69; P = 0.005), or be Black/African American (OR = 3.40; P < 0.001). Similarly, patients who did not return the survey were more likely to have had any adverse event (OR = 1.80; P = 0.012), major adverse event (OR = 2.88; P = 0.007), readmission (OR = 2.13; P < 0.001), be discharged to a place other than home (OR = 1.71; P < 0.001), or stay in the hospital for longer than 3 days (OR = 1.89; P < 0.001). Discussion: After THA, the HCAHPS survey response rate was only 31.69% and completion of the survey correlated with demographic and perioperative variables. These findings suggest that the HCAHPS survey results should be interpreted as a skewed sample of the true surgical patient population. Nonresponse bias is an important factor to consider when evaluating healthcare quality, patient satisfaction survey results, and their effects on federal hospital reimbursement rates.

29 July 2025 in JAAOS: Global Research and Reviews
Verified
Journal Article
Open access
AHAri Samuel Hilibrand
Ari Samuel Hilibrand
AFAlexander R. Farid
Alexander R. Farid
VDVineet Desai
Vineet Desai
JLJeffrey K. Lange
Jeffrey K. Lange
VSVivek M. Shah
Vivek M. Shah
ACAntonia F. Chen
Antonia F. Chen
Introduction: Osteoarthritis (OA) severity does not always correlate with clinical symptoms in joint arthroplasty candidates. Identifying metrics that correlate with clinical symptoms may inform strategies for OA treatment and optimization of arthroplasty timing. This study investigates the relationship between the novel metric of preoperative step count (SC) and radiographic OA severity compared with standard measures of preoperative pain/function. Methods: A prospective cohort study was conducted on 611 preoperative primary hip and knee arthroplasty patients. A mobile application preoperatively collected daily SCs (30 days), pain levels (0 to 10), and PROMIS Global Physical (PROMIS-P) and Mental (PROMIS-M) scores. Total preoperative SCs were normalized, yielding steps/day-recorded. Reviewers assessed preoperative radiographs for Kellgren-Lawrence (KL) OA severity. Associations between OA severity, SCs, and patient-reported pain/function were assessed by ANCOVAs, t-tests, and linear regressions. Results: A total of 507 patients recorded steps. KL grade 4 (severe) patients took fewer steps/day-recorded than KL grade 1-3 patients (P = 0.01); among KL grade 1-3 patients, there were no significant differences (P = 0.16). No differences were observed in pain (P = 0.50) or PROMIS-P scores (P = 0.21) between KL grades. Steps were negatively correlated with BMI (P < 0.001) and age (P < 0.001). Men walked more than women (P < 0.0001). Preoperative steps were positively correlated with PROMIS-P scores (P < 0.001) and negatively correlated with pain (P = 0.003). Better mental health correlated with more steps (P = 0.009). Discussion: Preoperatively, KL grade 4 patients took fewer steps than KL grade 1-3 patients, yet their reported pain/function did not differ. This suggests that step counts provide additional information on joint degeneration unavailable from standard preoperative measures and may be useful in clinical decision making as a better clinical proxy for function than standard patient-reported metrics.

Verified
Journal Article
Open access
PDF file
CACagdas AKTAN
Cagdas AKTAN
CBChristina Breneman
Christina Breneman
OAOkan Argun
Okan Argun
NSNora Seeley
Nora Seeley
CACeren Atalar
Ceren Atalar
MSMutlay Sayan
Mutlay Sayan
Lymphovascular invasion is an adverse pathologic feature in prostate cancer, but its independent molecular drivers remain unclear due to strong confounding by tumor grade and stage. We performed a confounder-adjusted transcriptomic analysis of 403 TCGA-PRAD samples. Differential expression was adjusted for Gleason score and pathological T stage. A transcriptional profile associated with LVI was derived and tested in multivariable logistic and Cox proportional hazards models for biochemical recurrence-free survival, with bootstrap internal validation. After multivariable adjustment, 129 genes were independently associated with LVI. This gene set was overwhelmingly enriched for interferon-alpha/beta signaling and antiviral response pathways. A continuous composite score derived from this profile predicted a reduced risk of biochemical recurrence independently of standard clinicopathological factors (adjusted HR per unit = 0.911, 95% CI: 0.835–0.993, p = 0.033). Multi-omics integration revealed subtle promoter hypomethylation and strong correlations between methylation and expression for key interferon genes, supporting transcriptional regulation. We identify a robust, interferon-response transcriptional profile that specifically defines LVI in prostate cancer after accounting for major clinical confounders. This transcriptional signature provides independent prognostic information, refines the biological understanding of LVI, and presents a novel targetable pathway for further investigation.

1 July 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CLClaudia Y. Lee
Claudia Y. Lee
JSJeffrey S Smith
Jeffrey S Smith
TKTaylor Kohlmann
Taylor Kohlmann
EMEmily M. Meara
Emily M. Meara
UPUyen Pham
Uyen Pham
SRSudarshan Rajagopal
Sudarshan Rajagopal
G protein-coupled receptors (GPCRs) are targets for almost a third of all FDA-approved drugs. GPCRs are known to signal through both heterotrimeric G proteins and β-arrestins. Traditionally these pathways were viewed as largely separable, with G proteins primarily initiating downstream signaling while β-arrestins modulate receptor trafficking and desensitization in addition to regulating their own signaling events. Recent studies suggest an integrated role of G proteins and β-arrestins in GPCR signaling, however the cellular and biochemical requirements for G protein: β-arrestin interactions remain unclear. Here we show that G proteins and β-arrestins can directly interact. Through utilization of β-arrestin-biased receptors and artificially enforced β-arrestin relocalization, we demonstrate that recruitment of β-arrestin to the plasma membrane is sufficient to interact with the G protein Gαi. Using purified proteins, we show that Gαi directly interacts with β-arrestin. In addition, we find that Gαi family members differ in their degree of association with β-arrestin, and that a large degree of this selectivity resides within the alpha helical domain of Gαi. These findings delineate the cellular and biochemical conditions that drive direct interactions between G proteins and β-arrestins and illuminate the molecular basis for how they work together to effect GPCR signaling.

17 July 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
CLClaudia Y. Lee
Claudia Y. Lee
JSJeffrey S Smith
Jeffrey S Smith
TKTaylor Kohlmann
Taylor Kohlmann
EMEmily M. Meara
Emily M. Meara
UPUyen Pham
Uyen Pham
SRSudarshan Rajagopal
Sudarshan Rajagopal
G protein-coupled receptors (GPCRs) are targets for almost a third of all FDA-approved drugs. GPCRs are known to signal through both heterotrimeric G proteins and β-arrestins. Traditionally these pathways were viewed as largely separable, with G proteins primarily initiating downstream signaling while β-arrestins modulate receptor trafficking and desensitization in addition to regulating their own signaling events. Recent studies suggest an integrated role of G proteins and β-arrestins in GPCR signaling, however the cellular and biochemical requirements for G protein:β-arrestin interactions remain unclear. Here, we show that G proteins and β-arrestins can directly interact. Through utilization of β-arrestin-biased receptors and artificially enforced β-arrestin relocalization, we demonstrate that recruitment of β-arrestin to the plasma membrane is sufficient to interact with the G protein Gαi. Using purified proteins, we show that Gαi directly interacts with β-arrestin. In addition, we find that Gαi family members differ in their degree of association with β-arrestin, and that a large degree of this selectivity resides within the alpha helical domain of Gαi. These findings delineate the cellular and biochemical conditions that drive direct interactions between G proteins and β-arrestins and illuminate the molecular basis for how they interact.